ASH 2015 | The promise of second-generation PI3K inhibitors for CLL
John Gribben and Stephan Stilgenbauer
• 4 Dec 2015
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc and Stephan Stilgenbauer, MD, explain the clinical development of second-generation phosphoinositide 3-kinase (PI3K) inhibitors, including duvelisib, which inhibits the delta and gamma isoforms of PI3K, and TGR-1202, which inhibits the delta isoform of PI3K.
